Open-label, placebo-controlled, parallel group study in healthy volunteers to evaluate the effects of two single MT 400 [naproxen sodium/sumatriptan] or naproxen sodium tablets administered two hours apart on chromosomal aberrations in peripheral blood lymphocytes

Trial Profile

Open-label, placebo-controlled, parallel group study in healthy volunteers to evaluate the effects of two single MT 400 [naproxen sodium/sumatriptan] or naproxen sodium tablets administered two hours apart on chromosomal aberrations in peripheral blood lymphocytes

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2015

At a glance

  • Drugs Naproxen sodium/sumatriptan (Primary) ; Naproxen sodium
  • Indications Migraine
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 02 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top